{"schema_version":"secwatch.filing_event.v1","accession":"0001477932-24-004096","form_type":"8-K/A","ticker":"BGLC","cik":"0001737523","company_name":"BioNexus Gene Lab Corp","filed_at":"2024-07-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.361040+00:00","generated_at":"2026-05-31T23:22:17.666371+00:00","sec_items":["5.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"BioNexus Gene Lab Corp amends CEO/acting CFO compensation: base salary $35k/month effective July 1, 2024, plus back pay","bullets":["Base salary for CEO/acting CFO Su-Leng Tan Lee set at $35,000 per month effective July 1, 2024.","Company will recognize back pay at this rate from when Tan Lee began serving as CEO and CFO.","Inducement Award Entitlement to be finalized by Compensation Committee in Q3 2024.","Amendment approved by Compensation Committee on June 30, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001477932-24-004096","json":"https://secwatch.observer/filing/0001477932-24-004096.json","markdown":"https://secwatch.observer/filing/0001477932-24-004096.md","text":"https://secwatch.observer/filing/0001477932-24-004096.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1737523/000147793224004096/0001477932-24-004096-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1737523/000147793224004096/bglc_8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T23:22:17.666371+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}